AACR 2021 – Affimed wins, Oncternal loses
Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.
AACR 2021 preview – the early themes emerge
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
AD/PD 2021 – Donanemab has much still to prove
Full data on Lilly's Alzheimer’s antibody will disappoint some, and point to a long road ahead.
Lilly lines up its next shot at Alzheimer’s
Expectations are high ahead of a detailed look at donanemab data, but hopes for a fast path to market feel overblown.
Asco-GU – Clear blue water between Keytruda and kidney cancer rivals
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
Asco-GU – confirmatory Padcev trial throws a curveball
Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.
World Symposium – Orchard leads the crop of Hurler syndrome hopefuls
Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.
Asco-GU – Bristol in pole position with Opdivo’s adjuvant use
Bladder cancer is the fourth tumour type to give Opdivo a phase III adjuvant win, and the extent of the survival benefit is impressive.
World Lung 2020 – amivantamab puts more data behind the hype
But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?
